Consolidated CDER/CBER INDs renumbered
The Center for Drug Evaluation & Research will assign new numbers to a group of INDs that were transferred from the Center for Biologics Evaluation & Research in 2003. The 2003 consolidation of the two centers created INDs with duplicate numbers (1"The Pink Sheet" Sept. 15, 2003, p. 14). To resolve the problem, INDs numbered below 14,000 submitted to CDER before the consolidation will be given new numbers by adding 80,000 to the original IND number...
You may also be interested in...
FDA is actively recruiting to replace 20 staffers who have left the Center for Biologics Evaluation & Research since plans to consolidate with CDER were announced a year ago
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.